CD1D and neoplasm: Our proposed vaccine, NKT ligand-loaded CD1d+ cells carrying the tumor antigens that target dendritic cells and induces activation of innate immunity and antigen-specific CD4+ and CD8+ T cell responses, named artificial adjuvant vector cells (aAVC), should be efficacious [124,125].